Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.30
-4.9%
$9.32
$6.28
$18.49
$3.49B0.08227,796 shs60,308 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$55.30
-1.6%
$51.35
$23.30
$66.06
$3.44B2.221.33 million shs173,797 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$31.14
-1.8%
$33.49
$22.96
$43.15
$3.61B0.722.77 million shs310,012 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$16.23
-5.9%
$15.09
$3.06
$65.80
$884.65M1.75995,802 shs325,025 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
+1.40%-3.82%+2.75%+49.59%-36.96%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.13%-6.94%+17.32%+14.57%+82.38%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+1.24%+5.73%-7.41%+10.33%+14.89%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+1.83%+24.55%+11.51%+24.19%+1,724,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.30
-4.9%
$9.32
$6.28
$18.49
$3.49B0.08227,796 shs60,308 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$55.30
-1.6%
$51.35
$23.30
$66.06
$3.44B2.221.33 million shs173,797 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$31.14
-1.8%
$33.49
$22.96
$43.15
$3.61B0.722.77 million shs310,012 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$16.23
-5.9%
$15.09
$3.06
$65.80
$884.65M1.75995,802 shs325,025 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
+1.40%-3.82%+2.75%+49.59%-36.96%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.13%-6.94%+17.32%+14.57%+82.38%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+1.24%+5.73%-7.41%+10.33%+14.89%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+1.83%+24.55%+11.51%+24.19%+1,724,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
2.78
Moderate Buy$21.13105.12% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.75
Moderate Buy$56.572.30% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.85
Moderate Buy$95.50206.68% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.82
Moderate Buy$41.88158.01% Upside

Current Analyst Ratings Breakdown

Latest VOR, VKTX, TLX, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$55.00 ➝ $60.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOutperform$50.00 ➝ $65.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
UpgradeMarket PerformOutperform$70.00
5/4/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$55.00 ➝ $65.00
5/1/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Reiterated RatingBuy$125.00
4/30/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Set Price Target$95.00
4/30/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Lower Price TargetOverweight$105.00 ➝ $100.00
4/30/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
UpgradeStrong-Buy
4/27/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
UpgradeStrong-Buy
4/20/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Reiterated RatingSell (D)
4/20/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Reiterated RatingSell (D-)
(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$803.79M4.35$0.04 per share253.30$1.23 per share8.37
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M9.14N/AN/A$7.84 per share7.05
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$5.65 per shareN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-$7.12MN/AN/A60.58N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$386.83N/AN/AN/AN/AN/AN/AN/A

Latest VOR, VKTX, TLX, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
4/29/2026Q1 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.01-$1.37-$0.36-$1.37N/AN/A
2/20/2026H2 2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$0.0493-$0.01-$0.0593-$0.0070$421.50 million$206.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1.08
1.43
1.27
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
5.72
5.72
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1,184339.11 millionN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20116.11 million109.95 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
14054.19 million53.94 millionN/A

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$10.30 -0.53 (-4.90%)
As of 11:04 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$55.30 -0.91 (-1.62%)
As of 11:05 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$31.14 -0.58 (-1.83%)
As of 11:05 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Vor Biopharma stock logo

Vor Biopharma NASDAQ:VOR

$16.23 -1.02 (-5.91%)
As of 11:05 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.